Literature DB >> 7515263

Frequency of raised alpha-fetoprotein level among Chinese patients with hepatocellular carcinoma related to hepatitis B and C.

J F Tsai1, W Y Chang, J E Jeng, M S Ho, Z Y Lin, J H Tsai.   

Abstract

Antibody to hepatitis C virus (anti-HCV) was found to be an independent risk factor for hepatocellular carcinoma and raised serum alpha-fetoprotein (AFP) level. In addition, the frequency of raised AFP in patients with anti-HCV was higher than in those without (91.5% vs 65.2%, P = 0.0001).

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7515263      PMCID： PMC1969433          DOI： 10.1038/bjc.1994.227

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  9 in total

1.  Specificities of serum alpha-fetoprotein in HBsAg+ and HBsAg- patients in the diagnosis of hepatocellular carcinoma.

Authors:  H S Lee; Y H Chung; C Y Kim
Journal:  Hepatology       Date:  1991-07       Impact factor: 17.425

2.  UICC meeting on breast-cancer screening in pre-menopausal women in developed countries. Geneva, 29 September-1 October 1993.

Authors:  S Eckhardt; F Badellino; G P Murphy
Journal:  Int J Cancer       Date:  1994-01-02       Impact factor: 7.396

3.  Epidemiology and long term prognosis of hepatitis C virus infection in Japan.

Authors:  M Yano; H Yatsuhashi; O Inoue; K Inokuchi; M Koga
Journal:  Gut       Date:  1993       Impact factor: 23.059

4.  Hepatitis C virus antibody in hepatocellular carcinoma in Taiwan.

Authors:  J E Jeng; J F Tsai
Journal:  J Med Virol       Date:  1991-05       Impact factor: 2.327

5.  Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan.

Authors:  J F Tsai; W Y Chang; J E Jeng; M S Ho; L Y Wang; M Y Hsieh; S C Chen; W L Chuang; Z Y Lin; J H Tsai
Journal:  J Med Virol       Date:  1993-12       Impact factor: 2.327

6.  Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma.

Authors:  J C Sheu; G T Huang; L N Shih; W C Lee; H C Chou; J T Wang; P H Lee; M Y Lai; C Y Wang; P M Yang
Journal:  Gastroenterology       Date:  1992-10       Impact factor: 22.682

7.  Relationship of hepatitis B surface antigen to serum alpha-fetoprotein in nonmalignant diseases of the liver.

Authors:  D S Chen; J L Sung
Journal:  Cancer       Date:  1979-09       Impact factor: 6.860

8.  Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a case-control study.

Authors:  J F Tsai; W Y Chang; J E Jeng; M S Ho; Z Y Lin; J H Tsai
Journal:  Liver       Date:  1994-04

9.  Hepatitis C virus infection among patients with chronic liver disease in an area hyperendemic for hepatitis B.

Authors:  J F Tsai; J E Jeng; W Y Chang; Z Y Lin; J H Tsai
Journal:  Scand J Gastroenterol       Date:  1994-06       Impact factor: 2.423
  9 in total
  12 in total

1.  Assessment of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma in Middle Eastern patients.

Authors:  Faisal M Sanai; Samia Sobki; Khalid I Bzeizi; Shaffi A Shaikh; Khalid Alswat; Waleed Al-Hamoudi; Majid Almadi; Faisal Al Saif; Ayman A Abdo
Journal:  Dig Dis Sci       Date:  2010-04-16       Impact factor: 3.199

2.  Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review.

Authors:  Ryosuke Tateishi; Haruhiko Yoshida; Yutaka Matsuyama; Norio Mine; Yuji Kondo; Masao Omata
Journal:  Hepatol Int       Date:  2007-12-29       Impact factor: 6.047

3.  Hepatocellular carcinoma in developing countries: Prevention, diagnosis and treatment.

Authors:  Michael C Kew
Journal:  World J Hepatol       Date:  2012-03-27

4.  Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass.

Authors:  Stephen L Chan; Frankie Mo; Philip J Johnson; Deyond Y W Siu; Michael H M Chan; Wan Y Lau; Paul B S Lai; Christopher W K Lam; Winnie Yeo; Simon C H Yu
Journal:  HPB (Oxford)       Date:  2013-08-26       Impact factor: 3.647

5.  Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study.

Authors:  J F Tsai; J E Jeng; M S Ho; W Y Chang; M Y Hsieh; Z Y Lin; J H Tsai
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma.

Authors:  J F Tsai; J E Jeng; L Y Chuang; M L Yang; M S Ho; W Y Chang; M Y Hsieh; Z Y Lin; J H Tsai
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma.

Authors:  J F Tsai; J E Jeng; M S Ho; W Y Chang; M Y Hsieh; Z Y Lin; J H Tsai
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

8.  Antibody Arrays Identify Potential Diagnostic Markers of Hepatocellular Carcinoma.

Authors:  Hongbo Sun; Mei-Sze Chua; Dorothy Yang; Anya Tsalenko; Brian J Peter; Samuel So
Journal:  Biomark Insights       Date:  2008-01-21

9.  Clinical evaluation of serum alpha-fetoprotein and circulating immune complexes as tumour markers of hepatocellular carcinoma.

Authors:  J F Tsai; J E Jeng; M S Ho; W Y Chang; Z Y Lin; J H Tsai
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

10.  Serum alpha-fetoprotein level is higher in hepatitis C than hepatitis B infected chronic liver disease patients.

Authors:  Mathias Abiodun Emokpae; Babatunde Gabriel Adejumol; Aliyu Abdu; Nasiru Magaji Sadiq
Journal:  Niger Med J       Date:  2013-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.